Replimune Group (FRA:7R8) EV-to-EBIT : -0.85 (As of Jun. 23, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Replimune Group's Enterprise Value is €164.97 Mil. Replimune Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-193.02 Mil. Therefore, Replimune Group's EV-to-EBIT for today is -0.85.

The historical rank and industry rank for Replimune Group's EV-to-EBIT or its related term are showing as below:

FRA:7R8' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.28 Med: 0 Max: 0.51
Current: -0.85

During the past 8 years, the highest EV-to-EBIT of Replimune Group was 0.51. The lowest was -19.28. And the median was 0.00.

FRA:7R8's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs FRA:7R8: -0.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Replimune Group's Enterprise Value for the quarter that ended in Mar. 2024 was €143.40 Mil. Replimune Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-193.02 Mil. Replimune Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -134.61%.

Replimune Group EV-to-EBIT Historical Data

The historical data trend for Replimune Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group EV-to-EBIT Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EV-to-EBIT

Get a 7-Day Free Trial

-4.71

-12.57

-3.81

-2.82

-0.75

Replimune Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-2.82	-5.07	-2.99	-0.63	-0.75

Competitive Comparison of Replimune Group's EV-to-EBIT

For the Biotechnology subindustry, Replimune Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Replimune Group's EV-to-EBIT falls into.

Replimune Group EV-to-EBIT Calculation

Replimune Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	164.972	/	-193.023
	=	-0.85

Replimune Group's current Enterprise Value is €164.97 Mil.
Replimune Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-193.02 Mil.

Replimune Group (FRA:7R8) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Replimune Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-193.023	/	143.39725
	=	-134.61 %

Replimune Group's Enterprise Value for the quarter that ended in Mar. 2024 was €143.40 Mil.
Replimune Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-193.02 Mil.

Replimune Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Replimune Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group (FRA:7R8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (FRA:7R8) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

REPL:USA

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group (FRA:7R8) Headlines

No Headlines